FDA-cleared profile

ClearRead CT CAC

Riverain Technologies, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Aids physicians in assessing coronary artery calcification on non-gated, non-contrast standard- or low-dose chest CT.

Clinical role
Measurement or quantification
Images and patients
CT/CTA · Chest/coronary arteries
Key limitation
Keep in mind: Input is limited to slices up to 3 mm, and segmentations are not diagnostic.

Overview status: Source-reviewed overview

Report a correction

Evaluation pilot

Before you shortlist

Exact FDA record: K242188 · Agent source review · . This is not clinician review or local acceptance.

Within this record's scope

  • Consider for coronary-calcium assessment on non-gated, non-contrast chest CT in adults aged 30 or older.

Limits to check

  • Check the 3 mm slice limit. Calcium segmentation is informational and requires expert review; it is a different function from lung-nodule detection.

Questions for the vendor and your team

  1. Does the quote name the CAC module and installed release, rather than only the ClearRead brand?
  2. How will the team check source images, calcium scores and report delivery on representative local scans?

These questions are prompts for evaluation, not claims that licensing, compatibility, performance or price has been confirmed.

Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Measurement & analysis · source-reviewed 2026-11-12

Agent source review of original FDA labeling; not clinician sign-off or local workflow qualification.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Aids physicians in assessing coronary artery calcification on non-gated, non-contrast standard- or low-dose chest CT.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/coronary arteries Input: DICOM non-gated, non-contrast chest CT in adults aged 30 years or older.
  • Who uses it?Intended users: Physicians.
  • What does the software produce?Output: Per-artery and total Agatston scores, CAC categories, arterial age, illustrative segmentations, and optional DICOM Secondary Capture.
  • What is its most important limitation?Key limitation: Input is limited to slices up to 3 mm, and segmentations are not diagnostic.

Clinical takeaway. Clinical role: Aids physicians in assessing coronary artery calcification on non-gated, non-contrast standard- or low-dose chest CT.

Evidence takeaway. Evidence from the reviewed source record: The 510(k) summary reports 491 clinical-assessment cases from five sites and four CT manufacturers, with kappa 0.959 (95% CI 0.943-0.975) and Bland-Altman limits of agreement -12.20 +/- 437.84.

Evidence context: questions, not a score

Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.

K242188 · agent source review 2026-11-12 · exact submission

Existing study anchor: ClearRead CT CAC regulatory performance study summary. Tested version label: Exact product version not reported; regulatory study summarized for FDA submission K242188.

What was tested?

Standalone Agatston category/score agreement and calcium segmentation, not a reader workflow trial or patient-outcome study.

Source section: 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

On which cases and versions?

The clinical set had 491 cases across five sites and four CT manufacturers: 143 without CAC and 348 with CAC. Approximately 400 internal held-out cases were a separate assessment.

Source section: 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

What changed?

The summary reports quadratic-weighted category agreement and separate continuous-score Bland-Altman limits. These are different endpoints, not one combined accuracy result. Agreement is not cancer-detection sensitivity or proof of reduced work-up.

Source section: 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

What does this not establish?

The selected score-spanning cases do not establish natural clinical prevalence or patient outcomes. Category agreement, continuous-score agreement and segmentation overlap are different endpoints. No local integration or management benefit is established.

Source section: 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

Study design, population and missing context
evidence Role
Standalone CAC scoring assessment; internal development-held-out testing and the clinical assessment are reported as separate tests.

validation · 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

design
Standalone algorithm-versus-ground-truth assessment on non-gated, non-contrast chest CT.

validation · 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

setting
Not established: The reviewed regulatory summary does not establish this field for this study context.
training Population
Not established: The reviewed regulatory summary does not establish this field for this study context.
evaluation Population
491 clinical-assessment cases: 143 with no CAC and 348 with CAC. Approximately 400 internal held-out cases are a separate test, not an added clinical denominator.

validation · 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

reference Standard
Clinical CAC status and Agatston measurements used consensus ground truth from three radiologists; internal testing used manually outlined calcium masks.

validation · 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

comparator
Automatic Agatston categories and scores versus radiologist ground-truth categories and scores.

validation · 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

sites
Clinical assessment included five clinical sites.

validation · 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

scanner Protocol
Clinical assessment included four CT manufacturers; non-gated, non-contrast chest CT. Agatston scores were scaled to 3 mm.

validation · 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

sample Composition
Clinical set: 143 CAC-negative and 348 CAC-positive out of 491 cases. Positive cases were selected to span the score range, not a natural screening prevalence estimate.

validation · 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

sponsor Involvement
Manufacturer-prepared Riverain submission. Independent-investigator status is not stated.

regulatory summary · 510(k) summary, Testing Summary: Non-clinical Testing and Clinical Performance Testing

Public-label constraints

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Exact FDA submission K242188 · agent source review 2026-11-09 · ClearRead CT CAC

Authorized population

Adult patients 30 years of age or older.

Label age limits

Adult patients 30 years of age or older. No numerical upper bound transcribed.

Documented care setting

Not established: No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.

Modality and protocol

Non-gated, non-contrast, standard or low-dose chest CT.

Acquisition constraints

Operates on CT slice thickness up to 3 mm; Agatston total calibrated to 3.0 mm.

Exclusions and human review

Segmentations are illustrative, not for diagnostic use. Adjunctive information must not be used without clinical expert review.

Purpose
Aids physicians in assessing coronary artery calcification on non-gated, non-contrast standard- or low-dose chest CT.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Measurement or quantification
  • Exact FDA submission
  • Checked 2026-11-12

Controlled-vocabulary normalization: the 510(k) summary describes a computer aided quantification system whose primary output is the Agatston score; its segmentations are illustrative only and not for diagnostic use.

Required input
DICOM non-gated, non-contrast chest CT in adults aged 30 years or older.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA input and population scope.

Output and clinician action
Per-artery and total Agatston scores, CAC categories, arterial age, illustrative segmentations, and optional DICOM Secondary Capture.
  • Exact FDA submission
  • Checked 2026-09-15

FDA output description.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Physicians.
  • Exact FDA submission
  • Checked 2026-09-15

FDA comparison table also lists radiologists.

Limitations
Input is limited to slices up to 3 mm, and segmentations are not diagnostic.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA limitation boundary.

Evidence summary
The 510(k) summary reports 491 clinical-assessment cases from five sites and four CT manufacturers, with kappa 0.959 (95% CI 0.943-0.975) and Bland-Altman limits of agreement -12.20 +/- 437.84.
  • Exact FDA submission
  • Checked 2026-11-12

Manufacturer-prepared 510(k) summary in the FDA decision packet, not an independent FDA analysis.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The 510(k) summary reports 491 clinical-assessment cases from five sites and four CT manufacturers, with kappa 0.959 (95% CI 0.943-0.975) and Bland-Altman limits of agreement -12.20 +/- 437.84.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-12

Manufacturer-prepared 510(k) summary in the FDA decision packet, not an independent FDA analysis.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

ClearRead CT CAC regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K242188
  • Samplen=491
  • IndependenceIndependence not established

K242188

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K242188. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM non-gated, non-contrast chest CT in adults aged 30 years or older.

    Scope: Exact FDA submission. Exact FDA input and population scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K242188: ClearRead CT CAC

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · ClearRead CT CAC model card (K242188)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-11-12 does not establish this claim; it gives only an intended location of Medical Facility and no hosting model.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-12 ·

  4. Returned objects

    Source context, not route validation: Per-artery and total Agatston scores, CAC categories, arterial age, illustrative segmentations, and optional DICOM Secondary Capture.

    Scope: Exact FDA submission. FDA output description.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K242188: ClearRead CT CAC

  5. Viewer/worklist/report

    Unresolved route: Per-artery and total Agatston scores, CAC categories, arterial age, illustrative segmentations, and optional DICOM Secondary Capture.

    Scope: Exact FDA submission. FDA output description.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K242188: ClearRead CT CAC

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for ClearRead CT CAC; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242188
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA CT scope normalized to the controlled CT/CTA bucket; CTA is not implied.

Anatomy
Chest/coronary arteries
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA anatomy scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-12-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K242188 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Withdrawn - checked 2026-11-12 - Exact FDA submission

    Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-11-12 does not establish this claim; it gives only an intended location of Medical Facility and no hosting model.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K242188: ClearRead CT CAC

    U.S. Food and Drug Administration - Published 2024-12-03 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ClearRead CT CAC model card (K242188)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K242188

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K242188 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260166

Bunkerhill Contrast CAC

BunkerHill Health

Authorized purpose: Detect, localize, and estimate the burden of coronary artery calcification on contrast-enhanced chest CT during clinical care.

Modality
CT/CTA
Anatomy
Chest/coronary arteries
Decision
2026-03-06
FDA-cleared K253786

syngo.CT Coronary Cockpit

Siemens Medical Solutions USA, Inc.

Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-06-25
FDA-cleared K260324

Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

Canon Medical Informatics, Inc.

Authorized purpose: Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.

Modality
CT/CTA
Anatomy
Aortic valve/root, LVOT and ventricles, coronary ostia, cardiac structures, and iliac/femoral/abdominal aortic access vessels
Decision
2026-05-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history